valproic
acid
vpa
short
chain
fatti
acid
commonli
use
treatment
neurolog
disord
shown
inhibit
product
infecti
progeni
differ
envelop
virus
includ
prototyp
arenaviru
lymphocyt
choriomening
viru
lcmv
studi
investig
mechan
vpa
inhibit
lcmv
multipl
cultur
cell
vpa
reduc
product
infecti
lcmv
progeni
viru
propag
without
exert
major
blockag
either
viral
rna
protein
synthesi
rather
affect
cell
releas
specif
infect
lcmv
progeni
infect
cell
result
would
support
repurpos
vpa
candid
antivir
drug
combat
arenaviru
infect
arenavirus
envelop
virus
biseg
negativestrand
ns
rna
genom
life
cycl
restrict
cell
cytoplasm
buchmeier
rna
segment
use
ambisens
code
strategi
direct
express
two
gene
product
opposit
orient
separ
noncod
intergen
region
larg
segment
l
kb
encod
l
protein
rnadepend
rna
polymeras
small
ring
finger
protein
z
counterpart
matrix
protein
found
mani
envelop
ns
rna
virus
small
segment
kb
encod
viral
nucleoprotein
np
glycoprotein
gp
precursor
gpc
cotransl
cleavag
gpc
signal
peptidas
produc
amino
acid
stabl
signal
peptid
sp
subsequ
posttranslationalprocess
gpc
cellular
site
proteas
gener
peripher
virion
attach
protein
fusionact
transmembran
protein
trimer
form
spike
decor
viru
surfac
mediat
cell
entri
via
receptormedi
endocytosi
buchmeier
kunz
kunz
et
al
l
np
minim
transact
factor
requir
viru
rna
replic
gene
express
lee
et
al
wherea
product
infecti
particl
also
requir
gp
z
lee
et
al
latter
drive
forc
viru
bud
plasma
membran
buchmeier
sever
arenavirus
chiefli
lassa
lasv
junin
junv
caus
hemorrhag
fever
hf
diseas
human
repres
import
public
health
concern
within
endem
region
west
africa
lasv
argentina
junv
geisbert
jahrl
peter
moreov
evid
indic
global
distribut
prototyp
arenaviru
lcmv
neglect
clinic
relev
human
pathogen
barton
et
al
jahrl
peter
met
et
al
concern
arenaviru
infect
human
aggrav
exist
vaccin
junv
live
attenu
strain
licens
exclus
argentina
protect
lasv
induc
diseas
likewis
exist
antiarenaviru
therapi
limit
use
nucleosid
analogu
ribavirin
partial
effect
associ
signific
side
effect
snell
therefor
import
develop
novel
antivir
strategi
drug
combat
human
pathogen
arenavirus
shown
treatment
infect
cell
valproic
acid
vpa
branch
shortchain
fatti
acid
commonli
use
treatment
neurolog
disord
bruni
wilder
terbach
william
reduc
yield
infecti
progeni
differ
envelop
virus
like
reflect
vpamedi
impair
lipid
metabol
may
affect
differ
step
viru
life
cycl
vazquezcalvo
et
al
studi
investig
mechan
wherebi
vpa
inhibit
multipl
prototyp
arenaviru
lcmv
excel
model
studi
basic
aspect
molecular
cell
biolog
hf
arenavirus
present
evid
vpa
treatment
lcmvinfect
cell
significantli
reduc
product
lcmv
infecti
progeni
without
significantli
affect
level
viral
rna
protein
synthesi
rather
interf
cell
releas
specif
infect
virion
particl
vero
cell
grown
dulbecco
modifi
eagl
medium
dmem
invitrogen
contain
fetal
bovin
serum
fb
mm
lglutamin
mgml
streptomycin
uml
penicillin
stock
lcmv
armstrong
strain
lcmv
arm
triseg
recombin
lcmv
express
gfp
emonet
et
al
produc
infect
moi
cell
harvest
tissu
cultur
supernat
tc
h
postinfect
pi
clarif
min
tc
store
c
cell
infect
lcmv
indic
moi
min
adsorpt
time
viral
inoculum
remov
cell
monolay
wash
twice
dmem
fresh
medium
contain
fb
differ
concentr
valproic
acid
vpa
vehicl
ad
time
point
consid
h
pi
lcmv
titer
focu
form
unit
ffu
ml
determin
immunofocu
assay
battegay
briefli
serial
viru
dilut
use
infect
vero
cell
monolay
plate
h
pi
cell
fix
use
formaldehyd
phosphatebuff
salin
pb
permeabil
treatment
triton
pb
contain
bovin
serum
albumin
bsa
stain
mous
monoclon
antibodi
np
alexa
fluor
antimous
secondari
antibodi
molecular
probe
case
viru
titer
determin
base
gfp
express
altern
viru
titer
also
determin
standard
plaqu
assay
semisolid
agar
medium
describ
vazquezcalvo
et
al
total
cellular
rna
isol
use
trireag
molecular
research
center
equal
amount
rna
sampl
analyz
northern
blot
hybrid
use
pradiolabel
np
dna
probe
describ
cornu
de
la
torr
stock
solut
mm
vpa
sigma
prepar
freshli
dmem
use
final
concentr
mm
previous
describ
vazquezcalvo
et
al
case
infect
cell
drug
ad
adsorpt
min
effect
vpa
cell
viabil
determin
use
celltiterglo
luminisc
cell
viabil
assay
promega
briefli
cell
seed
plate
treat
increas
concentr
vpa
mm
h
cell
incub
celltiterglo
reagent
assay
perform
accord
manufactur
recommend
concentr
vpa
caus
toxic
tc
calcul
cell
transfect
pcaggsnp
pcaggsl
describ
lee
et
al
h
transfect
medium
replac
fresh
medium
contain
differ
concentr
vpa
level
chloramphenicol
acetyltransferas
cat
protein
cell
lysat
h
posttransfect
determin
enzymelink
immunosorb
assay
elisa
use
cat
elisa
kit
roch
catalog
cell
transfect
pcaggszflag
pcz
urata
et
al
empti
pcagg
pce
control
plasmid
use
lipofectamin
invitrogen
dna
five
h
transfect
medium
replac
fresh
media
contain
vpa
mm
h
later
viruslik
particl
vlp
contain
tc
cell
harvest
remov
cell
debri
centrifug
g
min
vlp
collect
ultracentrifug
g
min
sucros
cushion
cell
vlp
resuspend
lysi
buffer
mm
trishcl
ph
mm
edta
sodium
deoxychol
protein
analyz
sdspage
follow
western
blot
wb
cell
lysat
vlp
viral
particl
sampl
resolv
sdspage
follow
western
blot
use
rabbit
polyclon
serum
flag
epitop
cayman
catalog
monoclon
antibodi
mab
actin
santa
cruz
lcmv
np
mab
lcmv
mab
buchmeier
et
al
weber
buchmeier
first
antibodi
horseradish
peroxidas
hrp
conjug
either
antirabbit
flag
antimous
igg
second
antibodi
cell
infect
moi
lcmv
treat
mm
vpa
cultur
supernat
harvest
h
pi
clarifi
rpm
min
sorval
centrifug
use
rotor
clarif
step
cell
supernat
perform
rpm
min
beckman
coulter
optima
xp
ultracentrifug
use
rotor
viral
particl
collect
centrifug
sucros
cushion
pb
rpm
h
use
rotor
viral
particlescontain
pellet
resuspend
pb
store
lcmv
mockinfect
control
cell
monolay
grown
mm
dish
wash
three
time
phosphat
buffer
ph
fix
room
temperatur
rt
glutaraldehyd
buffer
cell
scrap
postfix
osmium
potassium
ferricyanid
h
wash
three
time
bidistil
water
treat
tanic
acid
phosphat
buffer
ph
min
cell
wash
buffer
bidistil
water
sampl
stain
uranyl
acet
rt
three
wash
bidistil
water
sampl
dehydr
ethanol
embed
taab
resin
taab
laboratori
neg
stain
purifi
lcmv
virion
fix
glutaraldehid
sampl
adsorb
min
copper
grid
coat
collodioncarbon
ioniz
grid
neg
stain
uranyl
acet
airdri
determin
viral
particl
concentr
two
independ
lcmv
prep
incub
known
concentr
polystyren
latex
particl
nm
agar
scientif
ltd
neg
stain
score
sampl
examin
use
jeol
electron
microscop
jeol
oper
imag
acquir
use
digit
camera
tvip
oneway
analysi
varianc
perform
statist
packag
spss
spss
inc
window
data
present
mean
standard
deviat
differ
consid
statist
signific
p
first
evalu
impact
vpa
treatment
viabil
cell
vpa
exhibit
toxic
concentr
tc
mm
h
treatment
mm
h
treatment
fig
vpa
notic
effect
cell
viabil
either
h
treatment
therebi
select
vpa
concentr
experi
examin
effect
vpa
lcmv
multipl
follow
infect
cell
low
moi
facilit
viru
detect
infect
cell
use
recombin
triseg
lcmv
express
gfp
emonet
et
al
treatment
infect
cell
vpa
mm
notic
effect
cell
surviv
durat
h
experi
result
larg
reduct
number
gfp
posit
cell
h
pi
fig
b
vpa
induc
reduct
number
virusderiv
gfp
posit
cell
correl
drastic
reduct
product
infecti
progeni
fig
wild
type
lcmv
lcmvwt
fig
obtain
similar
result
follow
infect
higher
moi
data
shown
ass
possibl
direct
effect
vpa
infect
lcmv
particl
describ
antivir
drug
envelop
virus
wolf
et
al
treat
equal
number
ffu
fig
wt
lcmv
fig
vpa
mm
vehicl
c
minut
follow
determin
viru
infect
result
experi
indic
vpa
notic
virucid
effect
either
lcmvwt
investig
dosedepend
antilcmv
activ
vpa
infect
moi
cell
presenc
increas
concentr
vpa
h
pi
determin
viru
titer
tc
vpa
inhibit
product
infecti
lcmv
progeni
dose
depend
manner
half
maxim
inhibitori
concentr
ic
mm
fig
select
index
si
tc
ic
next
examin
whether
vpa
treatment
effect
lcmv
rna
synthesi
use
northern
blot
nb
analysi
conduct
timecours
studi
lcmv
rna
synthesi
follow
infect
cell
low
moi
absenc
presenc
mm
vpa
fig
lcmv
rna
genom
replic
rna
transcript
np
mrna
exhibit
similar
kinet
peak
level
vehicleand
vpatreat
lcmvinfect
cell
howev
rna
level
vpatreat
infect
cell
slighter
lower
observ
vehicletr
h
pi
consist
observ
vpa
treatment
significantli
affect
express
level
cat
report
gene
produc
lcmv
minigenom
fig
observ
vpa
robust
inhibitori
effect
product
lcmv
infecti
progeni
without
significantli
affect
viral
rna
synthesi
led
us
consid
vpa
might
effect
viru
bud
z
protein
shown
main
drive
forc
arenaviru
bud
et
al
examin
effect
vpa
zmediat
bud
use
cellbas
assay
previous
describ
et
al
transfect
cell
pczflag
h
later
medium
replac
fresh
medium
contain
increas
concentr
vpa
h
posttransfect
collect
tc
prepar
cell
lysat
zcontain
vlp
isol
tc
describ
materi
method
level
z
cell
lysat
vlp
prepar
determin
wb
use
antibodi
flag
fig
observ
vpa
lowest
concentr
use
mm
caus
reduct
zmediat
bud
inhibitori
effect
augment
cell
treat
higher
mm
vpa
concentr
fig
cellular
level
z
slightli
reduc
nontreat
compar
vpatreat
cell
like
reflect
higher
rate
z
bud
vpa
nontreat
cell
note
previous
document
z
mutant
impair
bud
activ
accumul
within
cell
higher
level
wt
z
observ
vpa
inhibit
zmediat
bud
led
us
examin
whether
vpa
interf
viral
particl
releas
end
infect
moi
lcmv
cell
treat
vpa
mm
h
pi
collect
tissu
cultur
supernat
tc
prepar
cell
transmiss
electron
microscopi
tem
vehicl
vpatreat
lcmvinfect
cell
display
area
rich
vesicl
fig
contain
structur
featur
similar
previous
document
correspond
intracellular
lcmv
particl
martin
et
al
fig
suggest
vpa
exert
major
blockad
intracellular
assembl
lcmv
next
examin
whether
morpholog
size
infect
lcmv
progeni
particl
releas
infect
cell
affect
vpa
treatment
viral
particl
releas
tc
lcmvinfect
cell
treat
vpa
concentr
examin
tem
use
neg
stain
case
viral
particl
show
similar
morpholog
fig
size
fig
consist
previous
report
rodrigo
et
al
tc
infecti
titer
deriv
infect
cell
presenc
absenc
vpa
pfu
ml
respect
vpa
treatment
caus
decreas
tc
infect
reduct
number
total
virion
particl
releas
fig
vpamedi
reduc
incorpor
releas
particl
could
account
larg
reduct
specif
infect
releas
particl
examin
question
determin
western
blot
ratio
particl
isol
lcmvinfect
cell
absenc
presenc
vpa
fig
avail
antibodi
work
western
blot
use
surrog
level
present
particl
releas
supernat
lcmvinfect
cell
treatment
vpa
affect
significantli
ratio
compar
vpa
untreat
lcmvinfect
cell
previou
studi
report
vpa
exhibit
broadspectrum
antivir
reflect
abil
inhibit
multipl
envelop
virus
belong
five
differ
viral
famili
vpa
appear
exert
broadspectrum
antivir
activ
via
differ
mechan
thu
show
vpa
block
wnv
vsv
rna
replic
protein
synthesi
wherea
vpa
treatment
caus
drastic
reduct
releas
stabil
vsv
particl
vazquezcalvo
et
al
report
investig
mechan
wherebi
vpa
inhibit
multipl
prototyp
arenaviru
lcmv
result
shown
vpa
inhibit
robustli
product
infecti
lcmv
progeni
fig
minim
interf
viral
rna
synthesi
virusinfect
cell
fig
accordingli
vpa
treatment
affect
level
report
gene
whose
express
driven
lcmv
minigenom
system
fig
h
pi
ratio
npmrna
lcmvinfect
cell
consist
slightli
lower
vpatreat
cell
compar
untreat
control
cell
like
reflect
effect
vpa
treatment
product
infecti
progeni
affect
speed
viru
propag
throughout
cell
monolay
follow
infect
low
moi
faster
propag
lcmv
vpa
untreat
cell
result
slightli
faster
peak
level
genom
antigenom
rna
speci
accompani
initi
downregul
viral
transcript
vpa
document
exert
differ
effect
cell
includ
interrupt
butyr
acid
gaba
signal
ii
inhibit
histon
deacetylas
hdac
iii
modul
sodium
channel
activ
inhibit
glycogen
synthas
kinas
v
disrupt
membran
lipid
metabol
includ
phosphatidylinositol
shaltiel
et
al
tokuoka
et
al
venkataramani
et
al
wittenburg
et
al
xu
et
al
therefor
vpamedi
interfer
varieti
cellular
process
may
root
antilcmv
activ
vpa
howev
inhibit
hdac
unlik
mediat
antilcmv
activ
vpa
shown
hdac
trichostatin
affect
lcmv
multipl
vazquezcalvo
et
al
hand
number
studi
document
vpa
affect
lipid
composit
cellular
membran
shaltiel
et
al
terbach
william
tokuoka
et
al
xu
et
al
propos
vpa
treatment
could
alter
vsv
particl
composit
render
extracellular
particl
reduc
stabil
vazquezcalvo
et
al
arenavirus
replic
confin
cytoplasm
infect
cell
bud
progeni
viru
occur
mainli
plasma
membran
buchmeier
bud
arenavirus
plasma
membran
involv
associ
viru
ribonucleoprotein
core
hostderiv
membran
enrich
viral
surfac
gp
et
al
process
driven
z
protein
shown
drive
forc
arenaviru
bud
capul
de
la
torr
et
al
strecker
et
al
urata
et
al
zmediat
bud
involv
interact
host
cell
protein
includ
member
multivesicular
bodi
pathway
et
al
strecker
et
al
urata
et
al
interact
requir
myristoyl
z
posit
promot
z
associ
membran
perez
et
al
therefor
vpamedi
effect
lipid
metabol
may
also
contribut
impair
z
bud
effici
fig
cellbas
assay
et
al
note
vpa
exhibit
typic
linear
dosedepend
inhibit
either
product
lcmv
infecti
progeni
fig
z
bud
activ
fig
exact
mechan
vpa
inhibit
lcmv
multipl
remain
determin
may
involv
complex
combin
interact
would
exert
full
potenti
inhibitori
activ
vpa
reach
threshold
concentr
cell
could
account
nonlinear
dosedepend
inhibitori
activ
vpa
treatment
affect
morpholog
size
releas
viral
particl
fig
consist
effect
vpa
zmediat
bud
number
viral
particl
releas
medium
lcmvinfect
cell
significantli
lower
reduct
vpatreat
cell
compar
nontreat
control
fig
effect
howev
account
magnitud
inhibitori
effect
exert
vpa
treatment
product
infecti
progeni
reduct
suggest
vpa
affect
effici
particl
releas
also
specif
infect
find
similar
describ
vsv
infect
vazquezcalvo
et
al
effect
vpa
specif
infect
releas
viru
particl
relat
reduc
incorpor
surfac
viral
gp
viral
particl
fig
previous
comment
alter
cellular
lipid
metabol
induc
vpa
probabl
result
alter
lipid
composit
cellular
membran
lcmv
acquir
envelop
alter
could
behind
reduct
infect
releas
lcmv
particl
vpatreat
cell
report
liveattenu
vaccin
strain
junv
licens
use
argentina
protect
lasv
infect
likewis
current
antiarenaviru
therapi
limit
offlabel
use
ribavirin
partial
effect
associ
signific
side
effect
borio
et
al
result
describ
work
rais
possibl
therapeut
antivir
use
vpa
si
compound
consid
good
predictor
feasibl
develop
potenti
candid
antivir
drug
li
et
al
notabl
vpa
exhibit
si
lcmv
support
consid
vpa
good
antivir
drug
candid
arenavirus
note
vpa
current
use
epilepsi
treatment
therapeut
dose
rang
mgkg
result
concentr
vpa
plasma
mm
cramer
et
al
kanner
significantli
higher
ic
valu
determin
lcmv
mm
therefor
current
use
therapeut
dose
rang
vpa
might
exert
vivo
antivir
effect
arenavirus
anticonvuls
vpa
drug
current
use
treatment
neurolog
disord
human
reduc
multipl
lcmv
without
exert
major
blockag
either
viral
rna
protein
synthesi
rather
vpa
affect
releas
viral
particl
infect
cell
specif
infect
releas
virion
result
present
report
would
support
repurpos
vpa
candid
antivir
drug
combat
arenaviru
infect
vpa
treatment
inhibit
lcmv
multipl
cultur
cell
zmediat
bud
viral
rna
protein
synthesi
significantli
inhibit
vpa
treatment
vpa
reduc
infecti
progeni
higher
extent
log
physic
particl
valproic
acid
candid
antivir
drug
combat
arenaviru
infect
vpa
inhibit
product
infecti
lcmv
progeni
b
effect
vpa
product
lcmv
infecti
progeni
cell
infect
moi
either
lcmvwt
b
adsorpt
fresh
medium
without
vpa
mm
ad
viru
titer
tissu
cultur
supernat
tc
determin
immunofocu
assay
indic
time
pi
vpa
virucid
effect
lcmv
b
ffu
aii
lcmvwt
ffu
bii
incub
without
vpa
mm
minut
serial
viru
dilut
use
infect
vero
cell
monolay
plate
viru
infect
determin
immunofocu
assay
describ
materi
method
statist
signific
differ
control
vpa
indic
asterisk
p
vpa
ic
cell
infect
lcmvwt
fig
adsorpt
fresh
medium
contain
mm
vpa
ad
viru
titer
tc
determin
immunofocu
assay
h
pi
ic
valu
determin
curv
fit
discontinu
line
vpa
inhibit
zmediat
bud
cell
transfect
pcz
pce
presenc
indic
vpa
concentr
h
posttransfect
tc
collect
total
cell
lysat
prepar
vlp
isol
tc
describ
urata
et
al
level
z
cell
lysat
vlp
determin
western
blot
use
antiflag
antibodi
level
actin
cell
lysat
use
load
control
b
normal
level
z
bud
